Multi-modal Assessment of Gamma-aminobutyric Acid (GABA) Function in Psychosis
4상
완료
NCT04004416
| 대상 질환 | Schizophrenia, Bipolar Disorder, Healthy, Psychosis |
|---|
| 임상 단계 | 4상 |
|---|
| 스폰서 | University of Michigan |
|---|
| 상태 | 완료 |
|---|
| 참여자 수 | 143 명 |
|---|
| 중재(약물) | Placebo and fMRI, Lorazepam and fMRI |
|---|
| 시작일 | 2020년 1월 16일 |
|---|
| 완료일 | 2025년 2월 28일 |
|---|
| 결과 공개일 | 2026년 6월 17일 |
|---|
요약
The purpose of this study is to better understand mental illness and will test the hypotheses that, while viewing affective stimuli, patient groups will show increased blood oxygenation level dependent (BOLD) signal by fMRI after lorazepam. This study will enroll participants between the ages of 16 and 60, who have a psychotic illness (such as psychosis which includes conditions like schizophrenia, schizoaffective disorder, and mood disorders like bipolar disorder). The study will also enroll eligible participants between the ages of 18 and 60 without any psychiatric illness to compare their brains. The study will require participants to have 3-4 sessions over a few weeks. The initial assessments (may be over two visits) will include a diagnostic interview and several questionnaires (qols) to assess eligibility. Subsequently, there will be two separate functional magnetic resonance imaging (fMRI) sessions in which lorazepam or placebo will be given prior to the fMRI. During the fMRI, the participants will also be asked to answer questions. Additionally, the participants will have their blood drawn, vital signs will be taken, they will be asked to complete more qols, and women of ch
Blood Oxygen Level Dependent (BOLD) Change in Medial Frontal Cortex While Viewing Affective Pictures
Approximately 28 days · AU
| Early Psychosis Patients - Lorazepam 0.01 mg/kg | -0.174 ± 0.183 AU |
|---|
| Early Psychosis Patients - Lorazepam 0.02 mg/kg | -0.037 ± 0.138 AU |
|---|
| Early Psychosis Patients - Placebo | -0.177 ± 0.209 AU |
|---|
| Schizophrenia or Schizoaffective Disorder Patients - Lorazepam 0.01 mg/kg | -0.167 ± 0.12 AU |
|---|
| Schizophrenia or Schizoaffective Disorder Patients - Lorazepam 0.02 mg/kg | -0.046 ± 0.169 AU |
|---|
| Schizophrenia or Schizoaffective Disorder Patients - Placebo | -0.175 ± 0.207 AU |
|---|
| p-value | 0.938 |
| F-Value (Estimation of Variance) | .136 |
BENITIONS에서 보기
ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
전체 임상
이 페이지는 ClinicalTrials.gov의 공개 데이터를 정리한 것입니다. 의학적 조언이 아니며 투자 권유나 자문도 아닙니다. 반드시 전문의와 상담하세요.